Kwality Pharmaceuticals Posts Robust Q2FY27 Growth and Appoints B S R & Co
Kwality Pharmaceuticals Ltd · Change in Auditor · 12 Nov 2026, 6:37 pm
Kwality Pharmaceuticals Posts Robust Q2FY27 Growth and Appoints B S R & Co. Kwality Pharmaceuticals reported strong Q2FY27 consolidated revenue growth of 63% YoY to ₹181 crore (+11.7% QoQ), with EBITDA margin expanding to 27.5% from 23.4% in Q2FY26. Net profit doubled YoY to ₹50 crore as PAT margin reached 16%. Driven by international product registrations, management raised its FY27 revenue guidance to ₹720+ crore from ₹700 crore. Additionally, the company acquired 4 acres in Amritsar for Unit 7, secured Hungary EU-GMP certification, and appointed B S R & Co. LLP as statutory auditors following Vijay Mehra & Co.'s resignation on 12th Nov'26.
Original exchange filing (PDF)
More announcements from Kwality Pharmaceuticals Ltd
- Transcript of Earnings Conference Call - Q2FY2027 · 16 Nov 2026
- Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 - Recording of Investor/ Analyst Earnings Call held on November 13, 2026 · 14 Nov 2026
- Intimation under Regulation 30 of the SEBI(LODR), 2015 -Recording of Investor/ Analyst Earnings Call held on September 13, 2026 · 14 Nov 2026
- Investor Presentation for the quarter and half year ended unaudited financial results for 30-09-2026 · 12 Nov 2026
- Resignation of Statutory Auditor · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026. · 12 Nov 2026
- Approval of Unaudited Financial Results for the quarter and half year ended 30-09-2026 · 12 Nov 2026
- Intimation of Earnings Conference Call for Q2 FY 2026-27 & REVISED LINK FOR REGISTRATION · 13 Nov 2026
